Compare MOD & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOD | RDY |
|---|---|---|
| Founded | 1916 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 11.9B |
| IPO Year | 1995 | 2001 |
| Metric | MOD | RDY |
|---|---|---|
| Price | $231.19 | $14.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $223.71 | $16.90 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $1,352,500,000.00 | N/A |
| Revenue This Year | $23.05 | $7.72 |
| Revenue Next Year | $21.83 | $3.50 |
| P/E Ratio | $108.22 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.48 | $12.19 |
| 52 Week High | $323.25 | $15.67 |
| Indicator | MOD | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 35.80 | 55.60 |
| Support Level | $190.32 | $13.80 |
| Resistance Level | $238.19 | $14.71 |
| Average True Range (ATR) | 16.39 | 0.34 |
| MACD | -6.14 | 0.05 |
| Stochastic Oscillator | 4.31 | 47.88 |
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.